tacrolimus
Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.
Cross Reference
Introduction
To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with tacrolimus?
tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
- Antimicrob. Agents Chemother. (2)
- Am. J. Physiol. Renal Physiol. (1)
- Drug Metab. Dispos. (1)
- Others (1)
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with tacrolimus
PubChem Associated disorders and diseases
What pathways are associated with tacrolimus
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with tacrolimus?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with tacrolimus?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with tacrolimus?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with tacrolimus?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with tacrolimus?
There are no associated biomedical information in the current reference collection.
NCBI Entrez Crosslinks
All references with tacrolimus
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Garcia-Criado FJ et al. | Tacrolimus (FK506) down-regulates free radical tissue levels, serum cytokines, and neutrophil infiltration after severe liver ischemia. | 1997 | Transplantation | pmid:9293871 |
| Stevens RB et al. | Randomized trial of single-dose versus divided-dose rabbit anti-thymocyte globulin induction in renal transplantation: an interim report. | 2008 | Transplantation | pmid:18497677 |
| Arns W et al. | Pharmacokinetics and Clinical Outcomes of Generic Tacrolimus (Hexal) Versus Branded Tacrolimus in De Novo Kidney Transplant Patients: A Multicenter, Randomized Trial. | 2017 | Transplantation | pmid:28658202 |
| Sheikh AM et al. | Concomitant human immunodeficiency virus protease inhibitor therapy markedly reduces tacrolimus metabolism and increases blood levels. | 1999 | Transplantation | pmid:10440408 |
| Moxey-Mims MM | Increased incidence of insulin-dependent diabetes mellitus in pediatric renal transplant patients receiving tacrolimus (FK506) | 1999 | Transplantation | pmid:10440413 |
| Jordan ML et al. | Results of pancreas transplantation after steroid withdrawal under tacrolimus immunosuppression. | 2000 | Transplantation | pmid:10670637 |
| Ashokkumar C et al. | Allospecific CD154+ T-cytotoxic memory cells identify recipients experiencing acute cellular rejection after renal transplantation. | 2011 | Transplantation | pmid:21747326 |
| McGhee B et al. | Therapeutic use of an extemporaneously prepared oral suspension of tacrolimus in pediatric patients. | 1997 | Transplantation | pmid:9326429 |
| Budde K et al. | Conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in maintenance renal transplant recipients receiving tacrolimus: clinical, pharmacokinetic, and pharmacodynamic outcomes. | 2007 | Transplantation | pmid:17318074 |
| Tuteja S et al. | The effect of gut metabolism on tacrolimus bioavailability in renal transplant recipients. | 2001 | Transplantation | pmid:11397967 |
| Casey MJ et al. | Prolonged immunosuppression preserves nonsensitization status after kidney transplant failure. | 2014 | Transplantation | pmid:24717218 |
| Stifft F et al. | Lower variability in 24-hour exposure during once-daily compared to twice-daily tacrolimus formulation in kidney transplantation. | 2014 | Transplantation | pmid:24686426 |
| Kahan BD | An immunosuppressive triumvirate to minimize renal injuries associated with calcineurin antagonist therapy. | 1999 | Transplantation | pmid:10428260 |
| Washburn K et al. | Steroid elimination 24 hours after liver transplantation using daclizumab, tacrolimus, and mycophenolate mofetil. | 2001 | Transplantation | pmid:11726831 |
| Reichenspurner H et al. | Optimization of the immunosuppressive protocol after lung transplantation. | 1999 | Transplantation | pmid:10428269 |
| Pilmore HL et al. | Tacrolimus for the treatment of gout in renal transplantation: two case reports and review of the literature. | 2001 | Transplantation | pmid:11726837 |
| Sampaio MS et al. | Association of immunosuppressive maintenance regimens with posttransplant lymphoproliferative disorder in kidney transplant recipients. | 2012 | Transplantation | pmid:22129761 |
| Moxey-Mims MM et al. | Increased incidence of insulin-dependent diabetes mellitus in pediatric renal transplant patients receiving tacrolimus (FK506) | 1998 | Transplantation | pmid:9521193 |
| Tzakis AG et al. | Alemtuzumab (Campath-1H) combined with tacrolimus in intestinal and multivisceral transplantation. | 2003 | Transplantation | pmid:12792506 |
| Koenen HJ et al. | Superior T-cell suppression by rapamycin and FK506 over rapamycin and cyclosporine A because of abrogated cytotoxic T-lymphocyte induction, impaired memory responses, and persistent apoptosis. | 2003 | Transplantation | pmid:12792519 |
| Jain A et al. | Pharmacokinetics of tacrolimus in living donor liver transplant and deceased donor liver transplant recipients. | 2008 | Transplantation | pmid:18347534 |
| Alhamad T et al. | Targeting High Calcineurin Inhibitor Levels After Acute Rejection With Less Tremor: A New Strategy. | 2017 | Transplantation | pmid:28422926 |
| Robertsen I et al. | Use of generic tacrolimus in elderly renal transplant recipients: precaution is needed. | 2015 | Transplantation | pmid:25148382 |
| Tabasco-Minguillan J et al. | Insulin requirements after liver transplantation and FK-506 immunosuppression. | 1993 | Transplantation | pmid:7692637 |
| Sofi AA et al. | Bullous pemphigoid associated with acute renal allograft rejection. | 2010 | Transplantation | pmid:20145531 |
| Kaplan B et al. | Low bioavailability of cyclosporine microemulsion and tacrolimus in a small bowel transplant recipient: possible relationship to intestinal P-glycoprotein activity. | 1999 | Transplantation | pmid:10075604 |
| Lang T et al. | Production of IL-4 and IL-10 does not lead to immune quiescence in vascularized human organ grafts. | 1996 | Transplantation | pmid:8824477 |
| McDevitt-Potter LM et al. | A multicenter experience with generic tacrolimus conversion. | 2011 | Transplantation | pmid:21788920 |
| Eckhoff DE et al. | Tacrolimus (FK506) and mycophenolate mofetil combination therapy versus tacrolimus in adult liver transplantation. | 1998 | Transplantation | pmid:9458011 |
| Roth D et al. | Primary immunosuppression with tacrolimus and mycophenolate mofetil for renal allograft recipients. | 1998 | Transplantation | pmid:9458023 |
| Zhao W et al. | Pharmacokinetic interaction between tacrolimus and amlodipine in a renal transplant child. | 2012 | Transplantation | pmid:22450597 |
| Ciancio G et al. | A randomized trial of three renal transplant induction antibodies: early comparison of tacrolimus, mycophenolate mofetil, and steroid dosing, and newer immune-monitoring. | 2005 | Transplantation | pmid:16123718 |
| Irish W et al. | Three-year posttransplant graft survival in renal-transplant patients with graft function at 6 months receiving tacrolimus or cyclosporine microemulsion within a triple-drug regimen. | 2003 | Transplantation | pmid:14688516 |
| Murase N et al. | Hamster-to-rat heart and liver xenotransplantation with FK506 plus antiproliferative drugs. | 1993 | Transplantation | pmid:7682735 |
| Chisholm MA et al. | Coadministration of tacrolimus with anti-acid drugs. | 2003 | Transplantation | pmid:12973105 |
| Mourad M et al. | Sirolimus and tacrolimus trough concentrations and dose requirements after kidney transplantation in relation to CYP3A5 and MDR1 polymorphisms and steroids. | 2005 | Transplantation | pmid:16249748 |
| Woodle ES et al. | Tacrolimus therapy for refractory acute renal allograft rejection: definition of the histologic response by protocol biopsies. | 1996 | Transplantation | pmid:8878382 |
| Kershner RP and Fitzsimmons WE | Relationship of FK506 whole blood concentrations and efficacy and toxicity after liver and kidney transplantation. | 1996 | Transplantation | pmid:8878385 |
| Macedo C et al. | Long-term effects of alemtuzumab on regulatory and memory T-cell subsets in kidney transplantation. | 2012 | Transplantation | pmid:22343334 |
| Taylor-Fishwick DA et al. | Evidence that rapamycin has differential effects of IL-4 function. Multiple IL-4 signaling pathways and implications for in vivo use. | 1993 | Transplantation | pmid:7689258 |
| Higgins R et al. | Rises and falls in donor-specific and third-party HLA antibody levels after antibody incompatible transplantation. | 2009 | Transplantation | pmid:19300192 |
| Pascual J et al. | Authors' reply: cyclosporine A versus tacrolimus in steroid withdrawal strategies. | 2011 | Transplantation | pmid:21336083 |
| Steiner RW | Steroid withdrawal in kidney transplantation: the subgroup fallacy. | 2011 | Transplantation | pmid:21336084 |
| Fredericks S and Holt DW | TGF-beta quantitation can be tricky. | 1999 | Transplantation | pmid:10480399 |
| Schvarcz R et al. | Interaction between nelfinavir and tacrolimus after orthoptic liver transplantation in a patient coinfected with HIV and hepatitis C virus (HCV). | 2000 | Transplantation | pmid:10852623 |
| Hughes JR et al. | Blood levels of TGFbeta1 in liver transplant recipients receiving either tacrolimus or micro-emulsified cyclosporine. | 1999 | Transplantation | pmid:10480422 |
| Hewitt CW and Black KS | Comparative studies of FK506 with cyclosporine. | 1988 | Transplantation | pmid:2458644 |
| Cacciarelli TV et al. | Management of posttransplant lymphoproliferative disease in pediatric liver transplant recipients receiving primary tacrolimus (FK506) therapy. | 1998 | Transplantation | pmid:9808490 |
| Macphee IA et al. | Tacrolimus pharmacogenetics: the CYP3A5*1 allele predicts low dose-normalized tacrolimus blood concentrations in whites and South Asians. | 2005 | Transplantation | pmid:15729180 |
| Baggio B et al. | Relationship between plasma phospholipid polyunsaturated fatty acid composition and bone disease in renal transplantation. | 2005 | Transplantation | pmid:16314806 |